SAN MATEO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a private medical technology company dedicated to becoming the performance leader in acute ischemic stroke intervention, today announced the first patient enrollment in its SUMMIT MAX clinical trial. SUMMIT MAX is a randomized, controlled, multi-center trial to evaluate the performance of its next generation Monopoint Reperfusion System versus currently available aspiration catheter technology. The first patient was enrolled at Auckland City Hospital in New Zealand, followed shortly by a patient at West Virginia University Medicine in the United States.
"I am delighted to begin enrollment in the SUMMIT MAX Study,” said Dr. Ben McGuinness of Auckland City Hospital in New Zealand. “The early results from our initial experience with the Route 92 088 platform in the SUMMIT NZ Study demonstrated an 80% TICI 2b-3 first pass reperfusion rate. It is an exciting opportunity to evaluate the possibility of improving interventional stroke treatment, and I hope the results of this trial will benefit future stroke patients."
Read More: https://www.globenewswire.com/news-release/2022/02/08/2380790/0/en/Route-92-Medical-Announces-First-Patient-Enrollment-in-the-SUMMIT-MAX-Pivotal-Clinical-Trial-for-the-Monopoint-Reperfusion-System.html
Route 92 Medical® Announces First Patient Enrollment in the SUMMIT MAX Pivotal Clinical Trial for the Monopoint® Reperfusion System
MORGANTOWN, W.Va. – The WVU Rockefeller Neuroscience Institute was first institution in the United States to enroll a patient in the Route 92 Medical, Inc. SUMMIT MAX clinical trial. SUMMIT MAX is a randomized, controlled, multicenter trial to evaluate the performance of its next generation Monopoint™ Reperfusion System versus currently available aspiration catheter technology.